Randomized, Double-Blind, Parallel-Group, Single-Dose Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability and Immunogenicity of MSB11456, US-licensed Actemra® and EU-approved RoActemra® in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Tocilizumab (Primary)
- Indications Autoimmune disorders
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 18 Dec 2017 Status changed from not yet recruiting to recruiting.
- 23 Oct 2017 Planned initiation date changed from 17 Oct 2017 to 6 Nov 2017.
- 20 Sep 2017 New trial record